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ABSTRACT
Nuclear genome duplication is normally restricted to once per cell division, but 
aberrant events that allow excess DNA replication (EDR) promote genomic instability 
and aneuploidy, both of which are characteristics of cancer development. Here we 
provide the first comprehensive identification of genes that are essential to restrict 
genome duplication to once per cell division. An siRNA library of 21,584 human 
genes was screened for those that prevent EDR in cancer cells with undetectable 
chromosomal instability. Candidates were validated by testing multiple siRNAs and 
chemical inhibitors on both TP53+ and TP53- cells to reveal the relevance of this 
ubiquitous tumor suppressor to preventing EDR, and in the presence of an apoptosis 
inhibitor to reveal the full extent of EDR. The results revealed 42 genes that prevented 
either DNA re-replication or unscheduled endoreplication. All of them participate in 
one or more of eight cell cycle events. Seventeen of them have not been identified 
previously in this capacity. Remarkably, 14 of the 42 genes have been shown to 
prevent aneuploidy in mice. Moreover, suppressing a gene that prevents EDR increased 
the ability of the chemotherapeutic drug Paclitaxel to induce EDR, suggesting new 
opportunities for synthetic lethalities in the treatment of human cancers.
INTRODUCTION
Genome instability is an integral part of cancer 
development. Cells isolated from human cancers typically 
vary widely in chromosomal content with both structural 
and numerical alterations, and they exhibit high rates 
of genome instability, as demonstrated by the rapid 
restoration of genomic heterogeneity following clonal 
selection [1]. In fact, genome instability is generally 
reported as the accumulation of polyploid and aneuploid 
cells [2]. Polyploid cells contain multiple copies of the 
entire genome. Aneuploid cells have either gained or 
lost entire chromosomes or parts of chromosomes. They 
exist in up to 80% of cancers, and they are associated 
with a poor prognosis for recovery [3]. Moreover, 
genome sequencing reveals that up to 37% of all tumors 
have transitioned through a polyploid state during their 
development [4], suggesting that tumorigenesis is 
accelerated by transition through the inherently unstable 
polyploid state. The increased potential of neoplastic cells 
to evolve more aggressive sub-clones also has been linked 
directly to genome instability [5, 6]. In fact, aneuploidy 
and resistance to chemotherapeutic drugs increase when 
polyploid cells are induced in vitro from cells derived 
from cancers or from non-transformed cells [3].
Human development requires trillions of cell 
divisions wherein nuclear DNA replication (S phase) is 
restricted to once per cell division by multiple regulatory 
pathways [7, 8]. Developmentally programmed 
endoreplication (a repeated S phase without an 
intervening mitosis or cytokinesis) is rare in mammals, 
although it occurs frequently in ferns, flowering plants, 
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mollusks, arthropods, amphibians, and fish [9]. Two 
well characterized examples in mammals are the 
trophoblast giant cells required for embryo implantation 
and placentation, and the megakaryocytes required for 
platelet production [10]. Nevertheless, interruption of the 
mammalian cell division cycle by selective inhibition of 
specific genes can result in excess nuclear DNA replication 
due either to unscheduled endoreplication or to DNA re-
replication.
Antimitotic drugs, such as taxanes and vinca 
alkaloids, are useful cancer therapeutics, because 
they inhibit microtubule dynamics, thereby arresting 
proliferation when cells enter mitosis [11]. However, 
cells do not remain in mitosis indefinitely, because the 
anaphase-promoting complex (APC) is activated soon 
thereafter [12, 13]. Activation of the APC allows cells 
to re-enter G1 phase as tetraploid cells with either a 
single enlarged nucleus or several micronuclei [14]. This 
aberrant event is termed mitotic slippage, and it generally 
results in DNA damage and apoptosis. However, tetraploid 
cells, particularly those lacking a G1 checkpoint such 
as p53 or Rb deficient cancer cells, can proceed into 
S phase, thereby producing a single cell with a giant 
nucleus containing 8N DNA [15-17]. This constitutes 
‘unscheduled endoreplication’, an event that can also 
occur by suppressing expression of genes that are either 
essential for cytokinesis [18] or for entrance into mitosis 
[19-22].
DNA re-replication occurs when the block to origin 
licensing is interrupted during S phase, and cells begin 
to re-replicate their nuclear DNA prior to completing S 
phase. This results in partially replicated chromatids that 
accumulate in giant nuclei ranging from 4N through 8N 
or even greater [23, 24]. Since DNA replication forks 
are sensitive to DNA damage, particularly in the form 
of double-stranded breaks, DNA re-replication induces 
DNA damage. Normal cells respond to DNA damage by 
arresting cell proliferation until the damage is repaired 
[25], whereas a robust DNA damage response in cancer 
cells elicits apoptosis [26, 27].
Anecdotal evidence suggests that genome instability 
arises when cells depend on fewer genes to prevent 
aberrant cell cycle events such as DNA re-replication, 
endoreplication, mitotic slippage, and acytokinesis. 
Normal cells contain multiple pathways that can prevent 
DNA re-replication [28], whereas cancer cells often 
depend on a single pathway to prevent excess DNA 
replication. For example, some cancer cells rely solely 
on geminin to prevent DNA re-replication dependent 
apoptosis [29, 30]. This would account for the fact that 
geminin is over-expressed in many tumors, and the 
prognosis for recovery is inversely related to the level 
of geminin expression [31, 32]. Moreover, suppressing 
geminin expression can prevent tumor growth [33].
Given these reports, we reasoned that the transition 
from a normal cell to a cancer cell must involve changes 
in the mechanisms that restrict genome duplication to once 
per cell division. In other words, fluctuations in the activity 
of a protein that prevents EDR could result in aneuploid 
or polyploid cells. For example, all four subunits of 
the chromosome passenger complex restrict genome 
duplication to once per cell division in vitro, and prevent 
aneuploidy/polyploidy during mouse development [34-
37]. Thus, identification of the genes that are essential to 
prevent EDR in cancer cells would reveal the mechanisms 
that promote genomic stability by restricting genome 
duplication to once per cell division.
Previous efforts to identify such genes in genome-
scale profiles of cell cycle regulators in HeLa [38] and 
U2OS [39] cells were incomplete. For example, neither 
study identified geminin, and only 10% of the results from 
these studies overlapped. Therefore, we set out to identify 
the most comprehensive collection of genes whose activity 
is essential to prevent EDR by screening siRNAs in a 
cancer cell line with undetectable chromosomal instability. 
Candidates from this screen should include the genes 
previously documented to be essential in preventing EDR, 
as well as genes that have not yet been reported in this 
capacity. The candidates were then subjected to a battery 
of validation assays in order to confirm the identity of 
genes essential to prevent EDR. The results revealed 42 
genes that are associated with eight specific cell cycle 
events that restrict genome duplication to once per cell 
division; selective inhibition of any one of these genes 
induced EDR in cancer cells with an unusually stable 
genome.
RESULTS
Genes essential to prevent EDR in human cancer 
cells were first selected from a high throughput screen 
(HTS) for siRNAs that induced the accumulation of cells 
with a nuclear DNA content greater than mitotic cells 
and then validated by a four-step protocol. First, raw data 
were analyzed using multiple statistical criteria to select 
genes for which at least two of the three tested siRNAs 
produced signals significantly above the mean. Second, 
each well of the genes selected by statistical analysis was 
further analyzed by constructing DNA histograms of the 
distribution of cells throughout the mitotic cell cycle. 
Third, interacting partners of the genes whose suppression 
produced the strongest signals were then tested in order 
to build confidence in the importance of a specific cell 
cycle event in preventing EDR. Fourth, a new siRNA was 
used to validate the efficacy of all candidate genes using 
standard laboratory transfection and fluorescence activated 
cell-sorting (FACS) protocols to quantify the extent of 
EDR.
HCT116 cells were used in this screen, because they 
exhibit DNA damage–dependent and spindle-dependent 
checkpoints, and unlike most cancer cells, demonstrate no 
signs of chromosome instability [40]. Moreover, HCT116 
cells are very sensitive to siRNA suppression of GMNN/
Geminin [29] or FBXO5/Emi1 [41, 42], genes known to 
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induce a robust accumulation of excess nuclear DNA in 
both TP53+ and TP53- cells. These results were confirmed 
for wild-type HCT116 cells under standard laboratory 
conditions (Figure 1A) and in the HTS (Figure 1B). In 
each case, the fraction of cells with enlarged nuclei was 
equivalent to the fraction of cells with >4N DNA content.
Selecting candidate genes by statistical analysis
Each 384-well plate contained cells transfected with 
Ambion’s ‘silent siRNAs’ that established the baseline, 
defined as 0% signal, and wells with cells transfected with 
siRNA against the Geminin gene (GMNN) that defined 
a 100% signal. The HTS data were then normalized to 
these controls in order to eliminate any plate-to-plate 
variation [43]. The fraction of cells with a nuclear DNA 
content >4N for the median of the three siRNAs in the 
primary HTS was compared with the median nuclear DNA 
content of the entire HTS (Figure 1C). The primary screen 
produced 454 genes with at least two siRNAs ≥3 median 
absolute deviation (MAD) above the median, of which 
69 had at least two siRNAs ≥5MAD. Signals greater than 
5MAD contain the most reproducibly active molecules 
[44]. Therefore, genes were selected from the ≥3MAD but 
<5MAD group that bore some relationship to one or more 
genes in the ≥5MAD group, as determined by GeneGo 
(MetaCore). These genes were combined with the ≥5MAD 
group and rescreened using four additional siRNAs per 
gene. The results from the primary and secondary screens 
yielded candidate genes with three to seven siRNAs 
≥5MAD. To minimize the impact of off-target activities 
upon siRNA HTSs, ‘redundant siRNA analysis’ was 
applied by assigning a p-value to each gene based on 
how effectively all three of the siRNAs tested for that 
gene performed in the primary HTS [45]. Applying the 
criteria that candidates must have three or more siRNAs 
with an efficacy of ≥5MAD and that the log(p) for these 
siRNAs is greater than -2 yielded 59 candidates. Induction 
of DNA re-replication in cancer cells increases nuclear 
size and siRNAs against 11 of these genes increased the 
cell’s nuclear area at least 70% as much as the 1.6-fold 
increase induced by siRNAs against either GMNN. Only 
11 genes satisfied all these criteria: FBXO5 (7/7 siRNAs), 
GMNN (7/7), TPX2 (5/7), ESPL1 (7/7), INCENP (7/7), 
PLK1 (7/7), TOP2A (7/7), KIF11 (7/7), BIRC5 (4/7), 
CDCA8 (5/7) and AURKB (7/7) each had four to seven 
independent siRNAs that induced a significant fraction of 
cells (≥5MAD) to accumulate sufficient excess nuclear 
DNA (>4N) to form giant nuclei.
Selecting candidate genes by nuclear DNA 
content analysis
To determine the extent to which individual cells 
accumulated excess nuclear DNA, histograms of DNA 
content were constructed for each of the 64,752 siRNAs in 
the primary HTS. Since the final number of cells per well 
varied significantly, especially for genes whose depletion 
caused apoptosis, each histogram was extrapolated to 
represent 1000 cells per well. The fluorescence intensities 
were distributed into 25 intervals that covered the entire 
range of detected fluorescence. The results for each siRNA 
were then plotted as heat-maps in which the intensity of 
the color was proportional to the number of cells in the 
interval. Examples of the siRNAs with median effect for 
eight candidate genes, one negative gene, and the silent 
siRNA control are shown as heat maps (Figure 2A) and bar 
graphs (Figure 2B). In some cases, the position of nuclei 
with 2N DNA content (G1 phase cells) differed from the 
controls in the same plate. Differences in the amount of 
fluorescence per DNA unit that causes shifts in the DNA 
peaks positions of cell populations are routinely corrected 
during FACS by adjusting the laser PMT voltage of the 
instrument until the positions of the 2N or the 4N peak 
are the same for each sample [46]. Since the microplate 
cytometer used in the HTS did not make such corrections 
automatically, the data were corrected manually in order 
to ensure that cells with the same amount of DNA in each 
well have the same position in each histogram and the 
cell cycle phase distributions were calculated properly. 
If a shift in the positions of either the 2N (G1 phase) or 
4N (G2/M phase) peaks could not be identified clearly in 
the histogram, then the siRNA was listed as a candidate 
for validation by standard FACS analysis. Supplementary 
Figure S1 contains heat maps of the median siRNA for 
all 96 candidate genes. These data allowed calculation of 
fraction of cells with nuclear DNA content equivalent to 
G1 phase (2N), S phase (>2N<4N), G2/M phase (4N), 
apoptosis (<2N), or EDR (≥5N). Quantifying the fraction 
of cells with a nuclear DNA content ≥5N ensured that only 
true EDR events were scored and not the trailing edge of 
cells accumulating in G2 or M phase.
Validating candidate genes
Candidate genes were subjected to validation by 
transfecting cells under standard laboratory conditions 
with a new siRNA that did not overlap with any of the 
HTS siRNAs and then quantifying the DNA/cell by 
FACS analysis. The fraction of cells undergoing EDR 
was defined as those with a nuclear DNA content ≥5N and 
the fraction undergoing apoptosis as those with a nuclear 
DNA content <2N. The results were consistent with heat 
maps produced by the HTS (Figure 2C). Preliminary 
FACS data revealed that EDR signals <26% had only a 
1/16 chance of being validated. This was due in part to 
the lower resolution scans used to generate the HTS DNA 
histograms, as reflected in lower MAD values. On that 
basis, 96 candidate genes were selected (Supplementary 
Figure S1). This group included those with highest 
statistical analysis scores (Figure 2D).
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Figure 1: High throughput screen (HTS) for genes that prevent excess DNA replication. A. Transfection of cultured HCT116 
cells for 72 hours with Ambion’s silent siRNA (control), or siGMNN/Geminin, or siFBXO5/EMI1 revealed a 10-fold increase in the 
fraction of cells with enlarged nuclei (58% with siGMNN; 49% with siFBXO5) relative to cells transfected with control (5%). Top panels 
are phase contrast images. Bottom panels are fluorescent images of cells stained with Hoechst 33342. Control nuclei are colored blue, 
and giant nuclei colored green. Images are all 20X magnification. B. HTS using the same siRNAs gave comparable results. Fluorescent 
images of nuclei in a single well treated with control siRNA revealed 95% of the nuclei contain ≤4N DNA (blue), and 5% of the nuclei 
contained >4N DNA (green). In contrast, 44% of the siGMNN treated cells and 51% of the siFBXO5 treated cells contained nuclei with 
>4N DNA (green). The total number of cells in control siRNA samples (blue plus green nuclei) was equivalent to cells in untreated wells 
(100%), whereas siGMNN treated wells contained 28% as many cells as control wells, and siFBXO5 treated wells contained 14% as many 
cells. C. The signals from 64,752 siRNAs in the Ambion primary screen were normalized to ‘silent siRNAs’ (0% signal) and siGMNN 
(100% signal) [43]. The fraction of cells with a nuclear DNA content >4N for the median of the three siRNAs in the primary HTS was 
compared with the median nuclear DNA content of the entire HTS. Subsequent validation assays confirmed that FBXO5, GMNN, TPX2, 
ESPL1, INCENP, PLK1, TOP2A, KIF11, BIRC5, CDCA8 and AURKB were critical for restriction of genome duplication to once per cell 
division. 5MAD was equivalent to ≥19.3% cells with >4N nuclear DNA, 10MAD was 33.4%, and 16MAD was 50.4%.
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Figure 2: DNA content analysis and validation of HTS data. A. Heat maps were created of the distribution of cells with a nuclear DNA 
content from <2N to >12N. Ten examples are shown; Supplementary Figure 1 contains the complete list of 85 candidate genes. Darker shading 
indicates higher fraction of cells with the indicated DNA content. The percentage of cells in G1 phase (2N DNA), S phase (>2N<4N DNA), 
and G2/M phase (4N DNA) was calculated, as well as the percentage of cells undergoing apoptosis (<2N DNA) or excess DNA replication 
(≥5N DNA). B. The data in panel A were expressed as histograms. C. Independent siRNAs against 8 candidate genes (AURKB, ECT2, ESPL1, 
FBXO5, GMNN, KIF11, PLK1 AND TOP2A), as well as one non-candidate gene (RPL23), and a control siRNA were validated in TP53+ and 
TP53- isogenic HCT116 cells using standard siRNA transfection and FACS protocols. Supplementary Figure 2 contains all the FACS profiles for 
the 42 validated genes. D. The 21,584 genes tested in the HTS were plotted according to the percentage of cells with ≥5N nuclear DNA content 
when depleted by the median effect siRNA in the HTS. The 20 genes with the greatest effect on preventing EDR are indicated. Of the cells treated 
with silent siRNA (control), 11% contained ≥5N nuclear DNA. These data revealed the fraction of cells with nuclear DNA content equivalent to 
G1 phase (2N), S phase (>2N<4N), G2/M phase (4N), apoptosis (<2N), or EDR (≥5N).
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TP53 can affect the extent of EDR
Since the tumor suppressor gene TP53 is directly 
involved in multiple pathways that can block cell cycle 
progression, promote apoptotic death and prevent 
tetraploid cells from undergoing EDR [47], we considered 
the possibility that the level of observed EDR might be 
affected by TP53 activity. To test this hypothesis, the ability 
of several candidate genes to prevent EDR was assayed 
in both HCT116(TP53+) and HCT116(TP53-) isogenic 
cells that differ only in expression of TP53. The results 
revealed that depletion of either PLK1 or KIF11 resulted 
in a three to five-fold increase in detectable EDR in the 
absence of TP53 (Figure 2C). The significant effect of TP53 
expression prompted validation of all candidate genes in 
both TP53 positive and negative cells (Figures 4, 5, 6). 
The results revealed 12 genes for which EDR increased in 
HCT116(TP53-) cells by at least an additional 20% relative 
to HCT116(TP53+) cells (Supplementary Figure S3). Genes 
most affected by TP53 absence were PLK1 (+45%), CCNB1 
(+40%), PRC1 (+32%), and RACGAP1 (+34%).
Apoptosis can prevent detection of EDR
Since induction of EDR can induce DNA damage 
dependent apoptosis [29], the level of excess DNA 
might depend on how rapidly EDR triggers apoptosis. 
This hypothesis was confirmed by culturing cells in the 
presence of MLN4924, a small molecule that selectively 
inhibits cullin based ubiquitin ligases by preventing their 
neddylation [48]. FACS analysis (Figure 3A) revealed that 
accumulation of cells with ≥5N DNA (EDR signal) was 
followed rapidly by accumulation of cells with <2N DNA 
(apoptotic cells). Moreover, accumulation of apoptotic cells 
was accompanied by disappearance of EDR cells (Figure 
3B). To determine whether or not apoptosis was linked 
directly to EDR, apoptosis was inhibited by addition of 
Z-VAD(OMe)-FMK (ZVAD), an irreversible inhibitor 
of caspases. As expected, ZVAD inhibited apoptosis, and 
increased the fraction cells with excess DNA by 2.5-fold 
(Figure 3C, 3D). Therefore, validation of candidate genes 
was carried out in the presence and absence of ZVAD 
(TP53+ cells ±ZVAD; Figures 4A, 5A, 6A). ZVAD reduced 
the fraction of apoptotic signal with on average 23% 
(Supplementary Figure S3). With three exceptions (ESPL1, 
RBX1 and DTL), ZVAD increased the level of excess DNA 
an additional 5% to 10% relative to TP53+ cells alone.
EDR induced apoptosis reduced cell viability
The tables in Figures 4A, 5A and 6A include the total 
number of cells remaining in each validation assay, as well 
as the extent of EDR and apoptosis induced by the siRNA. 
The reduction in the number of cells remaining, relative to 
controls, revealed the efficacy of each siRNA tested under 
different experimental conditions. Reduced numbers of 
cells meant that the siRNA had depleted a gene required for 
cell proliferation. The fact that at least three independent 
siRNAs for each validated gene reduced the number of cells 
to a similar extent confirmed the specificity of the observed 
effects. Furthermore, some siRNAs exhibited different 
effects on either EDR or apoptosis when assayed either in the 
presence of ZVAD or in the absence of TP53. Nevertheless, 
they inhibited cell proliferation to similar extents, thereby 
confirming that the effects of ZVAD and TP53 on EDR and 
apoptosis were not experimental artifacts. For example, 
siRNA depletion of PLK1 in three different validation assays 
reduced cell proliferation to 30% of control, but the extent 
of EDR varied from 11% to 56%. Similar comparisons were 
made for CDCA5, RACGAP1 and TPX2. The fraction 
of cells with normal DNA content (2N-4N) revealed that 
induction of EDR induced apoptosis that resulted in reduced 
viability (Supplementary Figure S3).
Genes that prevent EDR restrict genome 
duplication to once per cell division
Of the 85 genes subjected to three validation assays, 
only 42 were validated as essential to prevent EDR (Table 
1). These genes induced an EDR signal in FACS profiles 
(Supplementary Figure S2) that was at least 5-fold above 
control cells in one or more assays (Supplementary Figure 
S3). Twenty-nine genes were validated in TP53+ cells. 
Addition of ZVAD revealed 11 additional genes. Assays 
in TP53- cells revealed an additional two genes. For 
example, CASC5 depletion induced EDR was detected 
only when apoptosis was inhibited, whereas CDP192 
depletion induced EDR only in the absence of TP53 
(Figure 3E). The validation assays with the most robust 
signal are presented in Figures 4, 5, and 6, and all the 
FACS profiles are presented in Supplementary Figure S2.
Sixteen of the genes in Table 1 were previously 
identified in two high throughput screens for cell cycle 
regulators [38, 39], and 11 other genes have been identified 
in single gene studies using either siRNA or a chemical 
inhibitor (cited below), thereby confirming that the criteria 
used for validation in the present study were adequate to 
identify all of the genes essential for preventing EDR 
in the cells tested. An extensive search of the literature 
revealed that 17 of the 42 genes (40%) in Table 1 have not 
previously been reported to prevent EDR. All 42 genes are 
components of specific cell cycle events that prevent either 
DNA re-replication or unscheduled endoreplication.
Origin licensing inhibition
Nuclear DNA replication occurs only once during 
each cell division. When S phase begins, assembly of 
prereplication complexes on chromatin (‘origin licensing’) 
is blocked until mitosis is completed. If licensing occurs 
during S phase, cells accumulate with a single enlarged 
nucleus containing heterogeneous amounts of DNA (>4N 
to 8N or more) that leads to DNA damage and apoptosis. 
Therefore, multiple pathways exist that can inactivate 
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the helicase loader during S phase (Figure 4B), thereby 
preventing both reloading of MCM helicases at activated 
replication origins, and licensing of new replication 
origins [23, 28, 49].
Four activities known to prevent origin licensing 
during S phase were essential to prevent DNA re-
replication: GMNN, FBXO5, CRL1 AND CRL4. 
GMNN and FBXO5 prevented EDR that induced TP53 
independent apoptosis (Figure 4A). GMNN binds to CDT1 
and prevents its ability to load MCM helicases onto DNA 
replication origins (Figure 4B). FBXO5 inhibits the APC, 
an E3 ubiquitin ligase that targets both GMNN and CCNA 
for degradation, thereby preventing their destruction until 
mitosis. Since the APC is also required for the metaphase 
to anaphase transition (Figure 6B), inhibiting the APC 
induces unscheduled endoreplication.
Figure 3: The EDR signal was increased when apoptosis was inhibited. A. HCT116 cells were treated with 0.2μM MLN4924 
(MLN), a specific inhibitor of neddylation, in either the presence or absence of 15μM ZVAD, a specific inhibitor of caspases. Cells were 
collected at the indicated times and subjected to FACS. The fraction of cells with ≥5N DNA content (representing EDR), and the fraction 
with <2N DNA content (representing apoptosis) were determined from the FACS data. B. The relationship between EDR and apoptosis as 
a function of time after addition of MLN is displayed in the absence (B) and in the presence (C) of ZVAD. D. In the presence of ZVAD, 
the rapid conversion of cells undergoing EDR into cells undergoing apoptosis 18 hours after addition of MLN was inhibited by ZVAD to 
reveal that 51% (not 18%) of the cells contain excess DNA. E. The results of the three validation assays (TP53+ cells, TP53+ cells +ZVAD, 
and TP53- cells) revealed that depletion of some genes (e.g. CASC5) induced EDR only when apoptosis was inhibited with ZVAD, while 
depletion of others (e.g. CEP192) induced EDR only in the absence of TP53.
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Cullin-RING based E3 ubiquitin protein ligases 
(CRLs) target proteins for ubiquitin-dependent 
degradation. They each contain a Cullin subunit. However, 
of the eight Cullin genes, only CUL1 was selected by the 
HTS and validated, revealing the importance of CRL1 
in preventing EDR. CRL1 consists of CRL1 targets the 
CDK-dependent phosphorylated forms of CDT1 and 
ORC1. Although CDK2·CCNA phosphorylation of CDT1, 
ORC1 and CDC6 inhibits their ability to load the MCM 
helicase onto replication origins and converts CDT1 and 
ORC1 into CRL1 substrates, neither CDK2 nor CCNA 
were found to be essential to prevent EDR. The reason 
presumably arises from redundant activities. CDK2 
activity can be replaced by CDK1, and CCNA by CCNE 
[8]. Alternatively, since CDK2 is normally required for 
initiation of S phase, EDR would not occur in its absence.
CRL4 contains five components, four of which 
(DTL, DDB1, RBX1 and NEDD8) were essential to 
prevent EDR. However, neither CUL4A nor CUL4B 
(either of which can serve in CRL4) were selected, 
because their function is redundant. CRL4 targets CDT1 
only when it is associated with PCNA and DNA. NEDD8 
and RBX1 (the RING subunit), essential components of 
all CRLs, were selected and validated in all three assays, 
consistent with a requirement for both CRL1 and CRL4 in 
preventing DNA re-replication.
Chromatin untangling
Topoisomerase II untangles sister chromatids when 
replication forks from neighboring replicons collide 
and terminate replication (Figure 5B), and it continues 
to untangle DNA during mitosis [50]. Depletion of the 
enzymatic subunit (TOP2A) of topoisomerase II (Figure 
5A, 5C; Supplementary Figure S2B) or inhibition 
by etoposide (Figure 7) induced EDR in the form of 
endoreplication. Therefore, TOP2A activity was essential 
only after DNA replication was completed. In contrast to 
siRNA, topoisomerase chemical inhibitors kill cells by 
trapping topoisomerases on DNA rather than by reducing 
enzymatic activity, which results in incomplete DNA 
replication and the appearance of aneuploid cells [51].
Figure 4: Genes that prevented premature origin licensing prevented DNA re-replication. A. Seven of the validated genes 
have functions that prevent origin licensing during S and G2 phases of the cell cycle (illustrated in B. dark boxes with white font). The 
results of the three validation assays (TP53+ cells, TP53+ cells +ZVAD, and TP53- cells) carried out on each gene are summarized in panel 
A, and the FACS profiles are in Supplementary Figure S2A. FACS profiles for the validation assay with the strongest EDR signal for five 
of these genes are in panel C. The FACS profiles are consistent with induction of DNA re-replication when one of these genes is depleted.
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Mitotic entry and maintenance
Of the genes involved in mitotic entry and 
maintenance, only eight were essential to prevent EDR 
(Figure 5A) with endoreplication type EDR (Figure 5C; 
Supplementary Figure S2B). The five-subunit condensin 
complex contributes to the assembly of condensed 
chromosomes and remains with the chromatids throughout 
mitosis [52]. siRNAs against either SMC2 or SMC4 
produced a moderate induction of endoreplication (Figure 
5A; Supplementary Figure S2B). LIN54, a member of 
the five-subunit core module of the DREAM complex 
(Figure 5B) that is essential for mouse development and 
viability [53], was also essential to prevent unscheduled 
endoreplication due to mitotic slippage [Figure 5A, 5C; 
Supplementary Figure S2B; [38]. LIN54 is required for 
expression of multiple proteins that are essential for 
mitotic entry, spindle assembly and sister chromatid 
cohesion [53]. CDK1·CCNB1 and PLK1 kinases 
phosphorylate multiple targets during initiation and 
maintenance of mitosis. PLK1 phosphorylates FBXO5 
just before nuclear envelope breakdown, thereby targeting 
it for ubiquitin-dependent degradation [54]. This allows 
CDC20 to either activate the APC or to be sequestered 
Figure 5: Genes essential for untangling chromatin and entrance into mitosis were also essential to prevent EDR.  
A. Twelve of the validated genes have functions that untangle chromatin from G2 phase until metaphase, drive cells from G2 phase into mitotic 
prophase, and assemble the mitotic spindle during the prophase to prometaphase transition (illustrated in B. dark boxes, light font). The results 
of the three validation assays (TP53+ cells, TP53+ cells +ZVAD, and TP53- cells) carried out on each gene are summarized in panel A, and the 
FACS profiles are in Supplementary Figure S2B, S2C. FACS profiles for the validation assay with the strongest EDR signals are in panel C. 
The FACS profiles are consistent with induction of endoreplication or mitotic slippage when one of these genes is depleted.
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by the spindle assembly checkpoint (Figure 6B). 
CDK1·CCNB1 promotes centrosome maturation and 
separation, chromosome condensation and mitotic entry 
after nuclear envelope breakdown [55]. siRNA against 
cyclin B1 (CCNB1) induced endoreplication, confirming 
that mitotic entry is essential to prevent endoreplication 
[21]. CCNB1·CDK1 prevents exit from mitosis by 
phosphorylating several APC subunits, including CDC20, 
thereby maintaining the APC in an active state (Figure 
6B). The protein kinase MASTL/Greatwall, inhibits 
Figure 6: Genes essential for completion of mitosis and cytokinesis were also essential to prevent EDR. A. Twenty-three of the 
validated genes have functions required for the spindle assembly checkpoint during prometaphase, maintenance of sister chromatid cohesion 
from S phase until metaphase, chromosome segregation during anaphase, or cytokinesis (illustrated in B. dark boxes, light font). The results 
of the three validation assays (TP53+ cells, TP53+ cells +ZVAD, and TP53- cells) carried out on each gene are summarized in panel A, and 
the FACS profiles are in Supplementary Figure S2D, S2E. FACS profiles for the validation assay with the strongest EDR signal for 12 genes 
are in panel C. The FACS profiles are consistent with induction of endoreplication or mitotic slippage when one of these genes is depleted.
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Table 1: ‘This study’ identified and validated 42 genes that are essential for preventing excess DNA replication in 
HCT116 cells
Genes essential to prevent EDR







































SGOL1/Sgo1/Shugoshin-like 1 + + +
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PP2A-B55 [56] to accelerate entry into mitosis and block 
exit from mitosis. Failure to inhibit PP2A-B55 arrests the 
cell cycle in G2 phase.
Mitotic spindle assembly
The bipolar mitotic spindle consists of microtubule 
filaments with one end attached to the kinetochore 
complex located at each chromosomal centromere, and 
the other end attached to one of the two centrosomes 
in the cytoplasm. Of the genes involved in spindle 
assembly, only PLK1, CEP192, TPX2, AURKA, KIF11 
and POC1A were essential to prevent EDR (Figure 5A, 
5B). PLK1 stabilizes the initial kinetochore-microtubule 
attachments and promotes spindle formation by 
activating the chromosome passenger complex through 
phosphorylation of BIRC5 [57]. Consequently, PLK1 
depletion induces EDR, mitotic arrest, monoastral 
spindle arrays, aneuploidy, and apoptosis. siPLK1 
induced EDR in TP53- cells, but extensive apoptosis in 
TP53+ cells (Figure 5C; Supplementary Figure S2B). 
CEP192 is critical for centrosome biogenesis; it binds 
Aurora kinase A (AURKA) and PLK1, targets them to 
centrosomes, and promotes sequential activation of both 
kinases via phosphorylation [58]. TPX2 is essential for 
spindle assembly and chromosome segregation during 
prometaphase [59]. TPX2 regulates the activity of KIF11/
Eg5, a kinesin that functions early in mitosis to push 
the spindle poles apart by pulling microtubules past one 
another. Suppression of KIF11 activity activates SAC, 
resulting in mitotic arrest [60]. TPX2 also stabilizes 
the active conformation of AURKA, which is required 
for building a bipolar spindle regulating centrosome 
separation and microtubule dynamics. POC1A and 
POC1B act together in human cells to ensure centriole 
integrity [61].
Spindle assembly checkpoint
Chromosome segregation is delayed until the 
kinetochores on sister chromatids are firmly attached 
to spindle fibers from opposite poles (metaphase). The 
spindle assembly checkpoint (SAC) prevents chromosome 
segregation by preventing CDC20 from joining the APC 
until metaphase has been achieved [62]. In the absence 
of SAC activity, ESPL1/Separase cleaves centromeric 
cohesin, and cells exit mitosis irrespective of chromosome-
spindle attachments due to ‘mitotic slippage’ [63].
SAC has four major components that involve at 
least 35 genes, of which 13 were required to prevent 
EDR (Figure 6A, 6B). CASC5 is a scaffold on which 
BUB1, BUB1B/BUBR1 and BUB3 assemble to form 
a precursor to the mitotic checkpoint complex (MCC) 
consisting of MAD2L1, BUB1B, BUB3 and CDC20. 
In the absence of complete kinetochore-microtubule 
attachments, the chromosome passenger complex (CPC), 
consisting of INCENP, BIRC5/Survivin, CDCA8/Borealin 
and AURKB/Aurora kinase B, promotes the recruitment 
Genes essential to prevent EDR














The first gene name is from the Human Gene Nomenclature Committee (HUGO). In some cases, other names are provided 
that appear in recent literature. These genes participate in one or more of eight cell cycle events (indicated). To our 
knowledge, 17 of these genes have not been identified previously (‘New’), whereas the remaining genes have been identified 
previously in high throughput screens on HeLa [38] and U2OS [39] cells, or in single gene studies using siRNAs or chemical 
inhibitors. Some studies reported the appearance of aneuploid or polyploid cells during mouse development (aneuploid/
polyploid), and some studies reported an increased incidence of tumorigenesis when the expression level of the indicated 
gene was altered (‘tumorigenesis’). See Discussion, ‘Excess DNA replication is linked to aneuploidy and tumorigenesis’.
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of the MCC to the kinetochore in a series of events 
catalyzed by the TTK/Mps1 kinase [57]. CPC activity is 
regulated by multiple phosphorylation events that involve 
CDK1·CCNB1, TTK, PLK1 and CHK1. The net result is 
that the SAC delays cells in prometaphase by preventing 
CDC20 from joining the APC to form an active ubiquitin 
ligase, thereby promoting correct kinetochore-microtubule 
attachments prior to chromosome segregation. The 
NDC80 complex allows kinetochores to maintain load-
bearing tip attachments during both microtubule assembly 
and disassembly [64]. All four CPC subunits, five of the 
eight proteins involved in MCC assembly (CASC5, TTK, 
BUB3, BUB1B and MAD2L1), the NUF2 subunit of the 
NDC80 kinetochore complex, and three of the 13 APC 
subunits were required to prevent EDR.
Figure 7: Chemical inhibitors also can induce EDR in cancer cells. MLN4924 (0.2μM) inhibits neddylation of cullin based 
E3 ubiquitin ligases. BI2536 (25nM) inhibits PLK1. Etoposide (2μM) inhibits TOP2A. VX680 (0.6μM) inhibits AURKA and AURKB. 
Nocodazole (50ng/ml) binds tubulin and inhibits polymerization of microtubules. Cells were culture for 3 days in the presence of the 
indicated chemical, and then subjected to FACS. A. The results of the three validation assays (TP53+ cells, TP53+ cells +ZVAD, and TP53- 
cells) carried out on each chemical inhibitor are summarized. B. FACS profiles for the validation assays with the strongest EDR signal. 
C. Addition of 15μM ZVAD to HCT116(TP53+) cells revealed that, on average, 50% of the cells with excess DNA underwent apoptosis. 
D. HCT116(TP53+) cells were treated for 3 days with 2μM Bleomycin, 2μM Irinotecan, 60nM Vincristine, or 20nM Paclitaxel and then 
subjected to FACS. ZVAD increased, on average, 2.5-fold the percentage of cells with >5N DNA content. E. Cells were transfected with 
siCCNB1 and 24 later Paclitaxel was added to determine whether or not depletion of a gene essential to prevent EDR could promote the 
ability of Paclitaxel to induce EDR. At low Paclitaxel concentrations (2nM), the effect of siCCNB1 was synergistic. F. FACS profiles of 
selected samples. All the FACS profiles are in Supplementary Figure S2F.
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Sister chromatid cohesion
Sister chromatids are linked together during S 
phase by cohesin rings. Disruption of these rings results 
in premature separation of sister chromatids [65]. 
CDCA5/Sororin maintains sister chromatid cohesion 
during S phase by preventing WAP1 from dissociating 
noncentromeric cohesin (Figure 6B). CDCA5 is 
phosphorylated by CDK1·CCNB1 during prophase and 
targeted for degradation by the APC during anaphase. 
Of the 14 genes involved directly in cohesin assembly, 
only CDCA5 was essential to prevent EDR (Figure 6A; 
Supplementary Figure S2C).
Non-centromeric cohesin is dissociated during 
prophase. PLK1 phosphorylates the cohesin subunit 
STAG1, and CDK1·CCNB1 phosphorylates CDCA5, 
which allows WAP1 to dissociate non-centromeric cohesin 
(Figure 6B). AURKB is also required, but its function 
is undefined. Centromeric cohesin is protected from 
phosphorylation by protein phosphatase 2A (PP2A), which 
is targeted to centromeres by SGOL1/Shugoshin-like. 
PP2A preserves centromeric cohesion until metaphase. 
PLK1, AURKB, ESPL1, SGOL1 and the ‘constant 
regulatory subunit A’ (PPP2R1A) of PP2A were essential 
to prevent EDR.
Chromosome segregation
Assembly of the metaphase spindle inactivates 
the CPC, which results in dissociation of the MCC. 
This allows formation of the APC·CDC20 complex that 
ubiquitinates PTTG1/Securin, a specific inhibitor of the 
ESPL1 protease (Figure 6B). Centromeric cohesin is 
removed during the metaphase to anaphase transition 
when ESPL1 cleaves the STAG2 subunit. ESPL1 was 
essential to prevent endoreplication (Figure 6A, 6C). The 
simultaneous destruction of PTTG1 and CCNB1 elicited 
by APC·CDC20 links chromosome segregation to the 
dissolution of the SAC during mitotic exit [66].
Cytokinesis
Cytokinesis begins with assembly of a contractile 
ring composed of a filamentous network of actin, myosin 
II, and septin [67]. Immediately following chromosome 
segregation, centralspindlin (KIF23, RACGAP1) links 
the mitotic spindle to the plasma membrane with the help 
of ECT2. Binding of ECT2 to RACGAP1 at the spindle 
midzone induces formation of the contractile ring, and an 
ANLN/Anillin ·ECT2 complex stabilizes its position. PRC1 
regulates formation of the midzone by stimulating PLK1 
phosphorylation of RACGAP1 to allow recruitment of ECT2 
to the central spindle. CHMP4B, a component of the ESCRT-
III complex, functions in the final stage of cytokinesis. All of 
these genes were essential to prevent EDR.
Chemical inhibitors confirmed siRNA results
The proteins identified above as essential 
to prevent EDR were selected by reducing their 
cellular levels using siRNA. To determine whether 
or not inhibiting their activity would produce a 
comparable result, HCT116(TP53+) cells ±ZVAD and 
HCT116(TP53-) cells were challenged with specific 
chemical inhibitors. MLN4924 inhibits neddylation 
of cullin based ubiquitin ligases essential for their 
activation. BI2536 inhibits PLK1. VX680 inhibits 
AURKB. Nocodazole inhibits mitotic spindle assembly. 
In each case, the chemical inhibitor recapitulated 
the siRNAs ability to induce EDR (Figure 7A) as 
well as the type of EDR (Figure 7B). MLN4924, like 
siNEDD8, induced DNA re-replication. BI2536 and 
VX680, like siPLK1 and siAURKB, respectively, 
induced unscheduled endoreplication due to mitotic 
slippage. Nocodazole, a specific inhibitor of microtubule 
assembly, like siINCENP, siBIRC5, siAURKB and 
siCDCA8 (the chromosome passenger complex) induced 
unscheduled endoreplication due to mitotic slippage. 
Moreover, in each case, ZVAD increased the level of 
EDR from 2 to 2.5-fold (Figure 7C). Thus, chemical 
inhibitors specific for proteins previously identified 
by siRNA suppression of gene activity confirmed the 
importance of at least five cell cycle events in preventing 
EDR in cancer cells.
Several chemotherapeutic drugs induce EDR in 
cancer cells
Several drugs currently used in cancer chemotherapy 
also induced EDR, as demonstrated by a significant 
increase in the fraction of cells with excess DNA when 
challenged in the presence of ZVAD (Figure 7A). About 
70% of broadly based chemotherapeutic regiments 
include an inhibitor of topoisomerase II. In the presence 
of ZVAD, Etoposide, a specific inhibitor of topoisomerase 
II activity, increased the level of EDR by 2.4-fold (Figure 
7D). Similar results were obtained with Bleomycin (a 
DNA intercalating drug that induces DNA damage), 
Irinotecan (a Topoisomerase I inhibitor), Vincristine (an 
inhibitor of microtubule polymerization), or Paclitaxel 
(an inhibitor of microtubule depolymerization) (Figure 
7A, 7D). The significance of EDR induction by various 
chemotherapeutic drugs was revealed only when apoptosis 
was inhibited with ZVAD. However, the full extent to 
which cells accumulate with excess DNA is limited by 
two facts: ZVAD inhibition of apoptosis is incomplete, and 
these drugs induce extensive DNA damage leading quickly 
to apoptosis. Thus, induction of EDR is, to some extent, 
part of the mode of action for several drugs currently used 
in cancer chemotherapy.
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Synergistic effects between chemotherapeutic 
drugs and siRNA
Suppression of genes that prevent EDR should 
stimulate the level of EDR induced by chemotherapeutic 
drugs, thereby enhancing the ability of chemotherapeutic 
drugs to induce aneuploidy and cell death. To test this 
hypothesis, CCNB1, a gene essential to prevent EDR 
in cancer cells, was depleted with siRNA, and then 
the cells were treated with increasing concentrations 
of Paclitaxel (Figure 7E). ZVAD also was included to 
inhibit apoptosis. The results revealed that Paclitaxel and 
siCCNB1 acted synergistically to induce EDR (Figure 7F). 
Paclitaxel alone at 2nM induced EDR in 3% of the cells, 
and siCCNB1 alone induced EDR in 20% of the cells. 
However, combining the two treatments induced EDR in 
39% of the cells. This represented a 70% increase over the 
sum of the two treatments alone.
DISCUSSION
A basic concept in oncology is that the genomic 
instability characteristic of cancer cells permits the 
rise of aneuploidy and polyploidy. One source of this 
genomic instability is a reduction in the number or 
the effectiveness of pathways that prevent EDR. In an 
effort to relate these two concepts, we undertook the 
first comprehensive identification of genes that prevent 
EDR by screening about 95% of the human genome 
(21,584 genes) for genes that prevent EDR in HCT116 
cells, a colon cancer cell line with a stable, near diploid, 
karyotype [40] that is also available as isogenic cells 
differing only by the presence of a functional TP53 gene 
[68]. The results revealed 42 genes that prevented EDR 
by way of eight specific cell cycle events (Table 1). 
Seventeen of these genes have not been demonstrated 
previously in this capacity. Remarkably, 14 of the 
42 genes have been shown to prevent aneuploidy or 
polyploidy during mouse development, and eight of 
them to prevent tumorigenesis.
This screen identified only those genes whose 
function could not be replaced completely by that of 
another gene. This screen did not select any gene that 
is required for either DNA synthesis or replication, 
because accumulation of excess DNA requires these 
processes. This screen relied upon the results of three to 
seven independent siRNAs. Validation assays included 
an additional independent siRNA and specific chemical 
inhibitors where available. Validation assays were done on 
both TP53+ and TP53- cells in order to determine whether 
or not this tumor suppressor enhanced or diminished 
EDR. These results revealed that TP53 does not prevent 
initiation of EDR, although in some cases, the TP53 
DNA damage response activity reduced the extent of 
EDR. Examples include CUL1, LIN54, CCNB1, PLK1, 
CDCA5, CDC26, PRC1 and RACGAP1 (Supplementary 
Figure S3). Testing siRNAs in the presence of an apoptosis 
inhibitor insured that the EDR FACS signal was not lost 
due to DNA damage induced apoptosis. These results 
revealed that suppressing expression of some genes not 
only induced EDR, but triggered extensive apoptosis, 
thereby significantly reducing the EDR signal. Examples 
include GMNN, CUL1, LIN54, BIRC5, CDCA8 and 
CASC5 (Supplementary Figure S3). In fact, the ability 
of several genes to prevent EDR was affected both by 
inactivation of TP53 and inhibition of apoptosis. Examples 
include CUL1, LIN54, BIRC5, CDCA8, TTK and 
CHMP4B (Supplementary Figure S3).
An effort to determine whether or not over-
expression of the putative siRNA target gene reversed 
the effect of protein depletion by siRNA, several genes 
were expressed constitutively in HCT116 cells from a 
retroviral vector to insure protein expression throughout 
the period of siRNA transfection. Unfortunately, stable 
clones were not recovered. This was consistent with the 
essential function these genes have in regulating cell cycle 
progression (Table 1, Figure 8).
Excess DNA replication is linked to aneuploidy 
and tumorigenesis
Many of the same genes that prevent EDR in 
cultured cells also prevent aneuploidy or polyploidy 
during mammalian development or prevent tumorigenesis 
(Table 1). The systematic analysis of mouse models 
expressing haplo-insufficient and/or hypomorphic alleles 
of mitotic checkpoint components has revealed that 
reduced expression of such proteins leads to increased 
chromosome instability and aneuploidy. Fourteen genes 
that are essential to prevent EDR in cancer cells also 
are essential to prevent aneuploidy in mice [AURKA, 
BUB1B, BUB3, KIF11, MAD2L1, TPX2, TTK, SGOL1 
[59, 69-78]. The fact that the reduced expression of these 
genes leads to aneuploidy in mice establishes a direct 
link between genes identified as essential to prevent 
EDR and genes that are essential to prevent aneuploidy 
in vivo. Ablation of the genes for ESPL1, PLK1 or any 
one of the four subunits of the chromosome passenger 
complex (INCENP, BIRC5, CDCA8, AURKB) results 
in aneuploidy/polyploidy during mouse development 
[34-37, 79, 80]. Mutations in genes essential to prevent 
EDR appear to contribute to the development of specific 
cancers. For example, ANLN and PRC1 were mutated 
in cells derived from a malignant melanoma [81], and 
RANBP2, TTK, PP2R1A, and CEP192 were mutated 
in cells from pancreatic cancers [82]. Moreover, PLK1, 
TPX2, KIF11, AURKA, MAD2L1, TTK, SGOL1, ESPL1 
not only prevent aneuploidy/polyploidy, but also prevent 
tumorigenesis [59, 74-80]. These results suggest that all 42 
genes in Table 1 are essential to prevent aneuploidy and 
tumorigenesis.
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DNA re-replication versus unscheduled 
endoreplication
All of the 42 genes in Table 1 participate in eight 
specific cell cycle events that occur at different times 
during the mammalian cell cycle (Figure 8). Therefore, 
each of these events plays an essential role in restricting 
genome duplication to once per cell division. In principle, 
genes that are essential to prevent EDR prevent either DNA 
re-replication or unscheduled endoreplication, depending 
on whether the gene’s function is required during S phase 
or after S phase, respectively. Endoreplication produces 
polyploid cells that result from one or more rounds of 
genome duplication in the absence of an intervening 
mitosis or cytokinesis. These cells contain a single nucleus 
with an integral multiple of 4N DNA. Consequently, they 
produce a distinctive FACS signature with peaks at 8N, 
16N and 32N DNA content. DNA re-replication, however, 
produces aneuploid cells that result from incomplete 
genome duplication. These cells contain a single nucleus 
with a heterogeneous DNA content between 4N and 8N. 
Consequently, their FACS signature is indistinguishable 
from aneuploid cells that result either from apoptotic 
polyploid cells, or from incomplete DNA replication 
during the S phase following mitotic slippage. Therefore, 
the FACS profiles of HCT116 cells (±ZVAD) transfected 
with a gene selective siRNA were sorted into those with 
and those without a strong, easily recognized, 8N peak. 
The results clearly revealed DNA re-replication occurred 
predominantly, if not exclusively, when the block to origin 
licensing during S phase was disrupted, and unscheduled 
endoreplication occurred predominantly, if not exclusively, 
Figure 8: Specific cell cycle events associated with either DNA re-replication or unscheduled endoreplication. The 
42 genes in Table 1 participate in one or more of eight cell cycle events that restrict genome duplication to once per cell division. FACS 
analyses of HCT116 cells (±ZVAD) transfected with the indicated siRNA (Supplementary Figure S2) revealed that some cell cycle events 
(indicated in red) prevented primarily endoreplication whereas others prevented primarily DNA re-replication (indicated in blue). See text 
for details. Origin licensing refers to the assembly of prereplication complexes during the anaphase to G1 phase transition. Origin activation 
refers to the assembly of initiation complexes during the G1 to S phase transition.
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when cells were prevented from entering and completing 
mitosis and cytokinesis (Figure 8).
Genes required for sister chromatid cohesion 
(CDCA5, SGOL1, PPP2R1A) or chromatin untangling 
(TOP2A) are active throughout S, G2 and early M phases, 
but they were not essential to prevent EDR until cells 
attempted to transit mitosis, and therefore their absence 
produced a strong endoreplication signal (Supplementary 
Figure S2B, S2C). In the case of TOP2A, selective 
inhibition by Etoposide, which causes DNA strand breaks, 
induced both endoreplication and DNA re-replication 
signatures (Supplementary Figure S2F), consistent with a 
requirement during S phase as well as G2 and M phases.
Other genes, such as those required for mitotic 
entry and maintenance (CCNB1, MASTL, PLK1, SMC2, 
SMC4), mitotic spindle assembly (KIF11, TPX2, AURKA, 
POC1A), spindle assembly checkpoint (AURKB, BIRC5, 
CDCA8, INCENP, CASC5, TTK, MAD2L1, BUB3, 
BUB1B), and chromosome segregation (ESPL1) produced 
a distinct population of cells with 8N and sometimes 16N 
DNA content. Since these profiles mimicked the effects 
of antimitotic drugs such as Nocodazole, and arrested cell 
division after completion of S phase, endoreplication was 
a consequence of mitotic slippage. Chemical inhibition of 
aurora kinases A and B (VX680) or PLK1 (BI2536) induced 
endoreplication to a much greater extent than did siRNAs 
against these genes, thereby confirming that their role in 
preventing endoreplication. Similarly, genes required for 
cytokinesis (ECT2, PRC1, RACGAP, CHMP4B, KIF23) 
also induce endoreplication, presumably by a mechanism 
analogous to mitotic slippage.
Genes that prevented origin licensing (GMNN, 
FBXO5, CUL1, and NEDD8) during S phase were 
essential to prevent DNA re-replication (Figure 4). 
FACS profiles in which one of these genes was inhibited 
revealed accumulation of cells with a continuous range of 
ploidy from 4N to 8N or greater as a result of incomplete 
DNA replication and the accumulation of double strand 
DNA breaks [29, 30]. Moreover, chemical inhibition of 
neddylation with MLN4924 (Figures 3A; Supplementary 
Figure S2F), which inhibits all Cullin-dependent ubiquitin 
ligases, resulted in a strong DNA re-replication signal, 
thereby confirming the effect of siNEDD8 and the 
requirement for both CRL1 and CRL4 in preventing origin 
licensing during S phase. Surprisingly, LIN54, a protein 
that binds directly to the CHR element in promoters of 
genes, such as CDK1, and whose depletion results in 
cytokinesis and mitotic defects exhibited both a strong 
DNA re-replication and a strong endoreplication FACS 
signature, suggesting that LIN54 regulates expression of 
genes required to prevent origin licensing during S phase, 
as well as genes required for mitosis.
Heterotypic multi-subunit complexes exemplified 
the fact that not all proteins within a single cell cycle 
event are essential to prevent EDR. Whereas the 
chromosome passenger complex required all four of its 
subunits to prevent EDR (Figure 6B), other complexes 
did not. Examples include the cullin-dependent ubiquitin 
ligases (Figure 4B), the Dream complex, Cdk1·CcnB1, 
and Condensin (Figure 5B), and the mitotic checkpoint 
complex and anaphase-promoting complex (Figure 6B). 
These differences revealed which subunits are both 
essential for activity and have a short enough half-life 
that their levels can be reduced effectively by a siRNA. 
Other subunits in the complex might be sensitive to 
specific chemical inhibitors. For example, CcnB1·Cdk1 
is essential for both entry and maintenance of mitosis, but 
only CcnB1 was identified by siRNA. However, selective 
chemical inhibition of Cdk1 activity also results in EDR 
[19-22]. In some cases, suppression of protein levels by 
siRNA might be insufficient to induce the phenotype. 
In other cases, some proteins might not be essential for 
the activity of a multi-subunit complex, or they might be 
replaced by another protein with similar activity. Thus, 
emphasis should be placed on identification of specific 
events or pathways rather than on specific genes.
Therapeutic potential
The effectiveness of chemotherapy drugs currently 
used against cancer could be due, at least in part, to 
induction of EDR-dependent apoptosis. For example, 
drugs that inhibit Topoisomerase I, Topoisomerase II, 
tubulin polymerization, or tubulin depolymerization, and 
drugs that induce DNA strand breaks also induced EDR. 
This was particularly evident when ZVAD was used to 
inhibit apoptosis. Furthermore, depletion of CCNB1, a 
gene essential for preventing EDR, increased the EDR-
inducing effect of Paclitaxel at low concentrations. Thus, 
inhibition of a gene that is essential to prevent EDR in the 
presence of an established chemotherapeutic drug, such 
as Paclitaxel, has the potential of creating a ‘synthetic 
lethal’, inhibiting two or more proteins that leads to cell 
death under conditions where inhibition of neither protein 
has the same effect.
The presence or absence of checkpoint control genes 
and proapoptotic genes, such as TP53, can dramatically 
effect affect induction of EDR (e.g. siPLK1), as can the 
efficiency at which EDR induces apoptosis. The true 
extent of EDR was observed only when apoptosis was 
impaired. In the presence of ZVAD, the EDR signal 
increased significantly above control levels for 26% 
of the validated genes. Similarly, comparing the effects 
of the same siRNA on isogenic cells that differ only 
in TP53 revealed clearly the essential role TP53 has 
in EDR elimination. In the absence of TP53 activity 
[e.g. HCT116(TP53-) cells], more extensive EDR was 
observed. One notable exception was the apparent effect 
of TP53 on CRL4 activity. Depletion of NEDD8, DTL or 
DDB1 produced higher levels of EDR in the presence of 
TP53, suggesting that TP53 promotes EDR when CRL4 
activity is suppressed.
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Simply knowing which genes are essential for 
preventing EDR reveals the pathways that are modified 
in cancer cells to promote genomic instability and its 
associated aneuploidy and consequently allow cancer cells 
to evolve so as to evade anti-cancer treatments.
MATERIALS AND METHODS
siRNA screen
A high throughput screen (HTS) that was originally 
developed to identify small molecules that induced 
accumulation of excess DNA in cancer cells [83] was 
adapted to screen the Ambion ‘Silencer Select Human 
Genome siRNA Library V4’ for genes that are essential to 
prevent EDR in human cells [43]. This library contained 
three unique non-overlapping siRNAs for each of 21,584 
genes, which represented about 95% of protein coding 
genes (Ensemble, GRCh37.p13) [84]. Each siRNA was 
transfected individually into HCT116 colorectal cancer 
cells, which were then cultured for three days before their 
DNA was stained with Hoechst 33342. Fluorescence 
emitted from the nucleus of individual cells attached 
to the surface of the plate was quantified. Isogenic 
HCT116(TP53+) and HCT116(TP53-) cells were provided 
by their originator, Dr. Bert Vogelstein, and cultured as 
described [68]. The cell lines were passed for fewer than 
3 months following recovery from the original aliquots 
and were regularly authenticated by Western blots analysis 
including their p53 status, growth, and morphology 
observation.
siRNA transfection
Cells were seeded in 6-well dishes at 0.7x105 cells 
per well to insure they were undergoing exponential 
proliferation until collection. Cells were transfected with 
a single siRNA (40nM) at one and two days post-seeding 
using RNAiMAX per manufacturer's instructions. During 
each medium replacement, floating cells were collected 
and added back to the wells in order to include detached 
apoptotic cells in the analysis. Cells were harvested by 
trypsinization three days after the first transfection and 
combined with detached cells.
Fluorescence activated cell sorting (FACS)
Cells were washed in phosphate buffered saline, 
and then 2x105 cells were stained with propidium iodide 
and subjected to FACS analysis [46] using a FACSCalibur 
flow cytometer (Becton Dickinson, Mountain View, 
CA) according to the manufacturer instructions. Special 
attention was given to insuring that the cells were well 
separated before FACS, and that cells with 2N DNA 
content were coincident from one analysis to the next. 
Data were analyzed using FCS Express (De Novo 
Software).
Chemical inhibitors
MLN4924, BI2536, Etoposide, VX680, 
Nocodazole, Paclitaxel, and Z-VAD(OMe)-FMK (ZVAD) 
were purchased from Cayman Chemical Company, USA.
Western immuno-blotting
Equal numbers of cells were collected, lysed in 
Laemmli sample buffer, and subjected to electrophoresis 
and protein immuno-blotting. Filters were probed with 
specific antibodies and the signals visualized with 
enhanced chemiluminescence (ThermoScientific).
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